|Chemical and physical data|
|Molar mass||260.184 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Perzinfotel (EAA-090) is a drug which acts as a potent NMDA antagonist. It has neuroprotective effects and has been investigated for the treatment of stroke, but lacks analgesic effects. Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.
- Kinney, WA; Abou-Gharbia, M; Garrison, DT; et al. (January 1998). “Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere”. J. Med. Chem. 41: 236–46. doi:10.1021/jm970504g. PMID 9457246.
- Sun, L; Chiu, D; Kowal, D; Simon, R; Smeyne, M; Zukin, RS; Olney, J; Baudy, R; Lin, S (Aug 2004). “Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride)”. Journal of Pharmacology and Experimental Therapeutics. 310 (2): 563–70. doi:10.1124/jpet.104.066092. PMID 15075380.
- Brandt, MR; Cummons, TA; Potestio, L; Sukoff, SJ; Rosenzweig-Lipson, S (June 2005). “Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity”. J. Pharmacol. Exp. Ther. 313: 1379–86. doi:10.1124/jpet.105.084467. PMID 15764736.
- Baudy, Reinhardt B.; Butera, John A.; Abou-Gharbia, Magid A.; Chen, Hong; Harrison, Boyd; Jain, Uday; Magolda, Ronald; Sze, Jean Y.; Brandt, Michael R.; Cummons, Terri A.; Kowal, Diane; Pangalos, Menelas N.; Zupan, Bojana; Hoffmann, Matthew; May, Michael; Mugford, Cheryl; Kennedy, Jeffrey; Childers, Wayne E. (2009). “Prodrugs of Perzinfotel with Improved Oral Bioavailability”. Journal of Medicinal Chemistry. 52 (3): 771–778. doi:10.1021/jm8011799. ISSN 0022-2623. PMID 19146418.